Denosumab for Treatment of Hypercalcemia of Malignancy

CONTEXT: Hypercalcemia of malignancy (HCM) in patients with advanced cancer is often caused by excessive osteoclast-mediated bone resorption. Patients may not respond to or may relapse after iv bisphosphonate therapy. OBJECTIVE: We investigated whether denosumab, a potent inhibitor of osteoclast-med...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Egile Nagusiak: Hu, Mimi I., Glezerman, Ilya G., Leboulleux, Sophie, Insogna, Karl, Gucalp, Rasim, Misiorowski, Waldemar, Yu, Bennett, Zorsky, Paul, Tosi, Diego, Bessudo, Alberto, Jaccard, Arnaud, Tonini, Giuseppe, Ying, Wendy, Braun, Ada, Jain, Rajul K.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Endocrine Society 2014
Gaiak:
Endocrine Care
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC4154084/
https://ncbi.nlm.nih.gov/pubmed/24915117
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1210/jc.2014-1001
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak